Summary What is already known on this topic?Chronic obstructive pulmonary disease(COPD)exacerbations increase household economic burden,but there is limited evidence from prospective cohort studies in China about the ...Summary What is already known on this topic?Chronic obstructive pulmonary disease(COPD)exacerbations increase household economic burden,but there is limited evidence from prospective cohort studies in China about the impact of vaccination on economic burden.What is added by this report?This study demonstrated the economic burden of COPD exacerbations,pneumonia,and hospitalization in COPD patients in China is substantial.Influenza vaccine and 23-valent pneumococcal polysaccharide vaccine(PPSV23),separately or together,were significantly associated with decreased economic burden.What are the implications for public health practice?Our study supports evidence on recommendations that COPD patients in China are offered both influenza vaccine and PPSV23.展开更多
基金National Key R&D Program of China(2017YFC1309304).
文摘Summary What is already known on this topic?Chronic obstructive pulmonary disease(COPD)exacerbations increase household economic burden,but there is limited evidence from prospective cohort studies in China about the impact of vaccination on economic burden.What is added by this report?This study demonstrated the economic burden of COPD exacerbations,pneumonia,and hospitalization in COPD patients in China is substantial.Influenza vaccine and 23-valent pneumococcal polysaccharide vaccine(PPSV23),separately or together,were significantly associated with decreased economic burden.What are the implications for public health practice?Our study supports evidence on recommendations that COPD patients in China are offered both influenza vaccine and PPSV23.
